A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis (COMB157G2301)
Open enrollment until approximately 900 participants enrolled.
Location of Study/Trial:
Clinic visits will be conducted in Sacramento, California at UC Davis Medical Center
People with relapsing remitting multiple sclerosis (MS) will be enrolled in about 40 countries around the world.
Michelle Apperson, MD, PhD
Assistant Professor of Clinical Neurology
Description of Study/Trial:
This study is being done to determine if people on ofatumumab have fewer MS relapses than those on teriflunomide. Participants will take either ofatumumab and placebo or teriflunomide and placebo for up to 30 months. Treatment is randomly assigned and neither the physician nor the participant will choose or know which treatment group they are in.
Sponsor and/or funding information: Novartis Pharmaceuticals